Accessibility settings

This paper is in the following e-collection/theme issue:

Non-Randomized Studies (funded, non-eHealth) (265) Consumer & Patient Education and Shared-Decision Making (1308) Human Factors and Usability Case Studies (1338) Health Services Research (692) HIV/AIDS/STI Prevention and Care (1309)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56892, first published .
APPLI logo: Assessing Perceptions and Preferences around Long-acting Injectables

Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York

Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York

Authors of this article:

Mary Kathryn Irvine1 Author Orcid Image ;   Rebecca Zimba2, 3 Author Orcid Image ;   Tigran Avoundjian1 Author Orcid Image ;   Meghan Peterson1 Author Orcid Image ;   Connor Emmert1 Author Orcid Image ;   Sarah G Kulkarni2 Author Orcid Image ;   Morgan M Philbin4 Author Orcid Image ;   Elizabeth A Kelvin2, 3 Author Orcid Image ;   Denis Nash2, 3 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

Journals

  1. Dawdani A, Dance K, McNulty M, Erguera X, Flores R, Smith M, Tsuzuki M, Pareek P, Balter L, Montgomery E, Johnson M, Sauceda J, Hickey M, Collins L, Colasanti J, Koester K, Christopoulos K. What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?. AIDS and Behavior 2026 View